Mouse model as an efficacy test for foot‐and‐mouth disease vaccines

Gnazzo, Victoria; Quattrocchi, Valeria; Soria, Ivana; Pereyra, Erica; Langellotti, Cecilia; Pedemonte, Andrea; López, Virginia; Marangunich, Laura; Zamorano, Patricia

doi:10.1111/tbed.13591

Cited by 9 publications

(12 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of the humoral immune response profiles obtained in the murine model were further confirmed in calves, as was reported by Gnazzo et al (2020) (Gnazzo et al, 2020).…”

Section: Discussionsupporting

confidence: 80%

“…Interestingly, a prevalence of IgG1 and IgG2b isotypes was detected in animals vaccinated with VLPs-ISPA. These are promising results because Gnazzo et al (2020) reported that in the mouse model, IgG1 and IgG2b isotypes are important in the protection against FMDV O1 Campos\sout. VLPs-ISPA-vaccinated animals showed higher IgG3 isotype levels than the VLPs-CA group.…”

Section: Discussionmentioning

confidence: 88%

“…Fresh D-MEM supplemented with 2% fetal calf serum (FCS) was added and the cells were incubated for 48 h at 37 * C in 5% CO 2 . It was considered that animals were infected if the cell monolayer presented cytopathic effects after a blind passage, as established in previous studies (Gnazzo et al, 2020;V Quattrocchi et al, 2011;Zamorano et al, 2010). Percentages of protection were calculated as: 100 x [protected/challenged mice].…”

Section: Selection Of Vlps Dose For Vaccine Formulationmentioning

confidence: 99%

“…Our laboratory has ample experience in a murine model that proved useful to evaluate the potency of FMDV vaccines (Batista et al, 2010;Bidart et al, 2020;Gnazzo et al, 2020;C Langellotti et al, 2012;Cecilia Langellotti et al, 2015;V Quattrocchi et al, 2011Valeria Quattrocchi et al, 2005;Romanutti et al, 2013;Zamorano et al, 2010). In this model, there is a correlation with the humoral and protective immune responses against infective FMDV that take place in cattle (Gnazzo et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

ISPA cage-like particle adjuvant enhances protection induced by A/Arg/2001 Foot and Mouth Disease Virus-Like Particles

Bidart

Mignaqui

Kornuta

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Foot-and-Mouth Disease Virus (FMDV) causes an acute disease with important economy losses worldwide. Currently available vaccines are based on inactivated FMDV and oil-adjuvants. The use of Virus-Like Particles (VLPs) for subunit vaccines has been reported to be promising since it avoids the biological hazard of using virus in vaccine production while conserving conformational viral epitopes. However, a more efficient and cost-effective adjuvant than those currently used is needed. Immunostimulant-Particle Adjuvant (ISPA) is an Immune Stimulating Complex (ISCOM)-type adjuvant formulated with dipalmitoyl-phosphatidylcholine, cholesterol, stearylamine, alpha tocopherol and QuilA. In the present work, we have evaluated the immune response against FMDV using VLPs and ISPA as adjuvant. VLPs (serotype A/Arg/01) were obtained by transient gene expression in mammalian cell cultures, and a previously developed murine model, able to predict the ability of a vaccine to induce protection in cattle, was used for vaccination experiments in a first approach. The VLPs-ISPA vaccine induced protection in mice against challenge and elicited a specific antibody response in sera. In a second approach, the VLPs-ISPA vaccine was tested in calves. Interestingly one vaccine dose was enough to induce total α-FMDV antibodies , as measured by ELISA, as well as neutralizing Abs. Antibody titers reached an Expected Percentage of Protection higher than 90%. The EPP index calculates the probability that livestock will be protected against a challenge of 10.000 bovine infectious doses after vaccination. Moreover, IFN-γ levels secreted in vitro by mononuclear cells of VLP-ISPA vaccinated animals were significantly higher (p <0.05) than in the non-adjuvanted VLPs group. Overall, the results demonstrate that VLPs and ISPA are a promising combination for the development of a novel FMD vaccine, since no infectious FMDV is used and a protective immune response can be induced in calves, comparable to that achieved with the commercial FMDV vaccine.

show abstract

“…The results of the humoral immune response profiles obtained in the murine model were further confirmed in calves, as was reported by Gnazzo et al (2020) (Gnazzo et al, 2020).…”

Section: Discussionsupporting

confidence: 80%

Section: Discussionmentioning

confidence: 88%

Section: Selection Of Vlps Dose For Vaccine Formulationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

ISPA cage-like particle adjuvant enhances protection induced by A/Arg/2001 Foot and Mouth Disease Virus-Like Particles

Bidart

Mignaqui

Kornuta

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Twenty-four hours later, viremia was evaluated as described earlier. Animals were considered protected if viremia was absent at this time point, as established in previous studies (4)(5)(6)(14)(15)(16). Percentages of protection were calculated as 100× (protected/challenged mice).…”

Section: Inactivated Fmdv Dose To Vaccine Formulationmentioning

confidence: 99%

A New Cage-Like Particle Adjuvant Enhances Protection of Foot-and-Mouth Disease Vaccine

et al. 2020

Self Cite

View full text Add to dashboard Cite

Foot-and-Mouth Disease (FMD) is an acute viral disease that causes important economy losses. Vaccines with new low-cost adjuvants that stimulate protective immune responses are needed and can be assayed in a mouse model to predict their effectiveness in cattle. Immunostimulant Particle Adjuvant (ISPA), also known as cage-like particle adjuvant, consisting of lipid boxes of dipalmitoyl-phosphatidylcholine, cholesterol, sterylamine, alpha-tocopherol, and QuilA saponin, was shown to enhance protection of a recombinant vaccine against Trypanosoma cruzi in a mouse model. Thus, in the present work, we studied the effects on the magnitude and type of immunity elicited in mice and cattle in response to a vaccine based on inactivated FMD virus (iFMDV) formulated with ISPA. It was demonstrated that iFMDV-ISPA induced protection in mice against challenge and elicited a specific antibody response in sera, characterized by a balanced Th1/Th2 profile. In cattle, the antibody titers reached corresponded to an expected percentage of protection (EPP) higher than 80%. EPP calculates the probability that livestock would be protected against a 10,000 bovine infectious doses challenge after vaccination. Moreover, in comparison with the non-adjuvanted iFMDV vaccine, iFMDV-ISPA elicited an increased specific T-cell response against the virus, including higher interferon gamma (IFNγ)+/CD8+ lymphocyte production in cattle. In this work, we report for first time that an inactivated FMDV serotype A vaccine adjuvanted with ISPA is capable of inducing protection against challenge in a murine model and of improving the specific immune responses against the virus in cattle.

show abstract

Dendritic cell-based biomimetic nanoparticles for foot-and-mouth disease induce robust cellular immunity

Gao,

Liu,

Lei

et al. 2024

Antiviral Research

View full text Add to dashboard Cite

Mouse model as an efficacy test for foot‐and‐mouth disease vaccines

Cited by 9 publications

References 48 publications

ISPA cage-like particle adjuvant enhances protection induced by A/Arg/2001 Foot and Mouth Disease Virus-Like Particles

ISPA cage-like particle adjuvant enhances protection induced by A/Arg/2001 Foot and Mouth Disease Virus-Like Particles

A New Cage-Like Particle Adjuvant Enhances Protection of Foot-and-Mouth Disease Vaccine

Dendritic cell-based biomimetic nanoparticles for foot-and-mouth disease induce robust cellular immunity

Contact Info

Product

Resources

About